Perrigo (NYSE:PRGO) Director Jeffrey C. Smith acquired 250,000 shares of the company’s stock in a transaction dated Tuesday, May 15th. The stock was acquired at an average cost of $75.21 per share, with a total value of $18,802,500.00. Following the purchase, the director now owns 528 shares of the company’s stock, valued at $39,710.88. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of PRGO stock opened at $76.21 on Friday. Perrigo has a 1 year low of $63.68 and a 1 year high of $95.93. The company has a current ratio of 2.08, a quick ratio of 1.48 and a debt-to-equity ratio of 0.53. The company has a market cap of $10.48 billion, a price-to-earnings ratio of 15.46, a P/E/G ratio of 1.78 and a beta of 0.77.
Perrigo (NYSE:PRGO) last issued its quarterly earnings data on Tuesday, May 8th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.12. Perrigo had a return on equity of 11.93% and a net margin of 2.59%. The business had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the business posted $1.05 earnings per share. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. equities research analysts anticipate that Perrigo will post 5.25 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the business. Dupont Capital Management Corp purchased a new stake in Perrigo during the fourth quarter valued at approximately $104,000. Twin Tree Management LP raised its position in Perrigo by 271.0% during the first quarter. Twin Tree Management LP now owns 2,223 shares of the company’s stock valued at $185,000 after purchasing an additional 3,523 shares during the period. Allianz Asset Management GmbH purchased a new stake in Perrigo during the first quarter valued at approximately $205,000. Dean Capital Investments Management LLC purchased a new stake in Perrigo during the first quarter valued at approximately $209,000. Finally, ARP Americas LP purchased a new stake in Perrigo during the fourth quarter valued at approximately $212,000. Institutional investors and hedge funds own 79.52% of the company’s stock.
A number of equities research analysts recently commented on the company. Canaccord Genuity set a $105.00 target price on Perrigo and gave the stock a “buy” rating in a research report on Monday, May 14th. Cantor Fitzgerald set a $107.00 target price on Perrigo and gave the stock a “buy” rating in a research report on Friday, February 9th. JPMorgan Chase reiterated a “neutral” rating and issued a $83.00 target price (up from $82.00) on shares of Perrigo in a research report on Monday, March 5th. ValuEngine downgraded Perrigo from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Finally, Oppenheimer set a $98.00 target price on Perrigo and gave the stock a “buy” rating in a research report on Friday, May 11th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $93.06.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.